Evidence-based management of rapidly progressing systemic sclerosis. - Wikidata - wikimedia - TriplyDB

Evidence-based management of rapidly progressing systemic sclerosis.

Evidence-based management of rapidly progressing systemic sclerosis.

http://www.wikidata.org/entity/Q37763779

about

My approach to the treatment of scleroderma Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis Systemic sclerosis: commonly asked questions by rheumatologists Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.Work productivity in scleroderma: analysis from the University of California, Los Angeles scleroderma quality of life study.Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise The prevalence and clinical correlates of an auscultatory gap in systemic sclerosis patients Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial Old medications and new targeted therapies in systemic sclerosis.Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis.Characterisation of an epigenetically altered CD4(+) CD28(+) Kir(+) T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry.Latest advances in connective tissue disorders.Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study.Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis.Autologous hematopoietic stem cell therapy in severe systemic sclerosis: ready for clinical practice?When there's smoke there's…scleroderma: evidence that patients with scleroderma should stop smoking.Idiopathic or connective tissue disease-associated interstitial lung disease: a case of HRCT mimicry.Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis.Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.Indications for hospitalization and in-hospital mortality in Thai systemic sclerosis.Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.

P2860

Q24618843-5EC48CC4-8E41-45B8-9795-476B4EFDC3AD Q26773161-F7661CCA-8F2D-406B-B2D7-BA22F5BC3CE0 Q27021067-23F69BE4-1960-4358-B9E5-77F393661FFF Q33956830-6F424AA7-9956-4F52-902B-1CC42D18AB05 Q35700148-3F6A91FE-9CCE-4A8E-A5BF-7887DEDB248C Q35784089-590846F8-5E9A-4124-B889-F4F445291AC5 Q35829760-8A48FBA1-9B64-4AF3-AB8E-78DFE9DB55D6 Q35961706-50A0F492-8E9C-4BE3-884E-C60279ABEBAC Q36154430-6051F919-FCC4-453C-9EAA-2F5CDE2B4EC5 Q36709262-3D651521-FD30-4EC0-8D1F-CE305F73F1E5 Q36773601-979A44C6-1F4F-4B78-BCE4-9C501628B41F Q37058776-0747934E-9E6E-4EE6-8F73-E2623407596B Q37690732-2EBF13F5-7D09-4767-8A4D-A34233BA07F6 Q38880396-6F1E485D-CDCC-4458-BD36-6EF5E080CA87 Q41066068-FB333FB0-05A0-4AAF-90F7-77AAD1AE8478 Q42507582-8B84FE23-B92F-40D4-BFC8-0617098E949F Q42693931-5FEB16A6-B911-480C-931F-781CBF1FA56F Q43160934-ED77553A-40C3-4AAD-90B1-D7C400FFCC5F Q43588809-0B140620-32F4-47AF-A1A5-EF37E1F7FD09 Q44282751-E72672F8-F5EC-4DDA-A61B-2E7B5AFC515A Q45007419-B150B091-9055-4292-9402-CC66356FD0DB Q46274957-A4B93648-E9BD-4AE4-A0B5-9A815B5B32E0

P2860

Evidence-based management of rapidly progressing systemic sclerosis.

http://www.wikidata.org/entity/Q37763779

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Evidence-based management of rapidly progressing systemic sclerosis.

@en

Evidence-based management of rapidly progressing systemic sclerosis.

@nl

type

label

Evidence-based management of rapidly progressing systemic sclerosis.

@en

Evidence-based management of rapidly progressing systemic sclerosis.

@nl

prefLabel

Evidence-based management of rapidly progressing systemic sclerosis.

@en

Evidence-based management of rapidly progressing systemic sclerosis.

@nl

P1433

Q37763779-6E4621D6-8796-4222-8DCC-94B148CD18CF

P1476

Q37763779-9D55DCA7-F069-44C3-A593-FBF9488C79C0

P2093

Q37763779-39AFF256-2F2E-4CB3-B88A-2047684523F3

Q37763779-ED76F673-F6F1-4FB4-8083-7E8A3940408D

P2860

Q37763779-00A96620-6CDA-4383-B6E1-66E4FA431B8E

Q37763779-0273853F-3279-4042-8779-45CD597681F4

Q37763779-064F6076-6CF6-46C4-8575-D4EEF2F40D15

Q37763779-10864336-8F1A-4B91-8CD3-20C444EE7DB2

Q37763779-10DA091E-4F3D-48AA-A604-FB6E883F3BD3

Q37763779-181E3BC4-08FA-48D9-BCF6-FB271140ECCB

Q37763779-1CAF8F78-1EA3-4878-A7D2-D6A8D01B7949

Q37763779-1D729B03-B6D5-4804-91C1-F1A99891B662

Q37763779-290BF02A-745F-4C21-B885-F2A2F8377A95

Q37763779-3125612D-9B0C-4E27-8CFB-465280075256

P304

Q37763779-12156C01-25CF-4DB1-BF4C-600C531AF2FE

P31

Q37763779-24D83D2A-91FB-4945-9533-F16AAF64773D

P356

Q37763779-0614A644-73ED-4024-998F-CAC315A5A64E

P433

Q37763779-C36B91A0-B0B0-44E9-93A6-55DCD6AF89DC

P478

Q37763779-3CE6BA1E-0EED-446A-8B95-4BFC78B7653D

P577

Q37763779-3104A19D-456D-4BF8-B877-FF191D2A83E7

P5875

Q37763779-5B2CC9F7-2D56-4A51-B67C-580335AFE4AA

P698

Q37763779-5F8732FA-D374-45FA-8F2F-D2A895FCDF28

P932

Q37763779-740832E9-81B3-439D-A1E9-EAC63BF5C0D2

P356

J.BERH.2009.12.002

P1433

Best Practice & Research: Clinical Rheumatology

P1476

Evidence-based management of rapidly progressing systemic sclerosis.

@en

P2093

Christopher P Denton

http://www.w3.org/2001/XMLSchema#string

Dinesh Khanna

http://www.w3.org/2001/XMLSchema#string

P2860

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).

Cyclophosphamide versus placebo in scleroderma lung disease.

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Scleroderma renal crisis: patient characteristics and long-term outcomes.

Non-invasive measurement of biomechanical skin properties in systemic sclerosis.

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.

Pulmonary arterial hypertension in systemic sclerosis: diagnostic pathway and therapeutic approach.

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-ph

P304

387-400

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BERH.2009.12.002

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44659985

http://www.w3.org/2001/XMLSchema#string

P698

20534372

http://www.w3.org/2001/XMLSchema#string

P932

2884006

http://www.w3.org/2001/XMLSchema#string